Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

2.2%

4 terminated/withdrawn out of 185 trials

Success Rate

95.8%

+9.3% vs industry average

Late-Stage Pipeline

21%

38 trials in Phase 3/4

Results Transparency

4%

4 of 91 completed trials have results

Key Signals

31 recruiting4 with results4 withdrawn

Enrollment Performance

Analytics

N/A
89(61.4%)
Phase 4
19(13.1%)
Phase 3
19(13.1%)
Phase 2
16(11.0%)
Phase 1
2(1.4%)
145Total
N/A(89)
Phase 4(19)
Phase 3(19)
Phase 2(16)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (185)

Showing 20 of 185 trials
NCT03331718Phase 3Completed

PoLyglycolic Acid Felt reiNforcEmenT of the PancreaticoJejunostomy (PLANET-PJ Trial)

Role: collaborator

NCT02433795Phase 2Completed

Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

Role: collaborator

NCT07505628Not ApplicableNot Yet Recruiting

AI-based Rehabilitation for Hip and Knee Surgery Patients

Role: lead

NCT07437573Phase 3Completed

Oncometabolic Surgery

Role: collaborator

NCT06086665Completed

The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer

Role: collaborator

NCT07311122Not Yet Recruiting

Endocrine Therapy Base on 21-gene RS

Role: lead

NCT07296406Not ApplicableEnrolling By Invitation

App-Based Self-Management for Somatic Symptom Disorder and MUS: A Pilot Study

Role: lead

NCT05146778Not ApplicableRecruiting

A Study to Reduce Persistent Post-mastectomy Pain Using Opioid-free Anesthesia

Role: lead

NCT07237555Active Not Recruiting

CVL Risk After Severe Glaucoma Surgery

Role: lead

NCT07211451Completed

Axillary Nodal Burden in HER2+ and TNBC

Role: lead

NCT07121478Phase 2Enrolling By Invitation

Patients With High-grade Pancreatic Neuroendocrine Tumors

Role: collaborator

NCT07025460Phase 4Active Not Recruiting

Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 Study

Role: lead

NCT07154485Phase 2Not Yet Recruiting

Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia

Role: collaborator

NCT04700436Phase 4Completed

Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia

Role: collaborator

NCT07100431Not ApplicableCompleted

Comparison of Safety and Clinical Effects of Straight and Articulated Instruments (ArtiSential) in Laparoscopic Gastrectomy for Gastric Cancer Patients, a Prospective Randomized Study

Role: lead

NCT07093775Not Yet Recruiting

Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score

Role: lead

NCT07091773Not ApplicableNot Yet Recruiting

A Clinical Trial to Evaluate the Safety and Effectiveness of OLIZ, a Photobiomodulation Medical Device for Surgical Site Pain Relief in Patients After Total Knee Arthroplasty

Role: collaborator

NCT05148286Phase 4Recruiting

Albumin and Crystalloid Administration in Septic Shock

Role: collaborator

NCT07011823Phase 2Not Yet Recruiting

Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC

Role: lead

NCT05333328Phase 4Recruiting

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

Role: lead